Abstract:Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate the development of personalized treatment strategies. The current precision medicine for lung cancer, primarily based on pathological and genomic multi-omics testing, fails to meet the needs of patients with clinically refractory lung cancer. Lung cancer organoids (LCOs) are derived from tumor cells within tumor tissues and are generated through three-dimensional tissue culture, enabling them to faithfully recapitulate in vivo tumor characteristics and heterogeneity. The establishment of a series of LCOs biobanks offers promising platforms for efficient screening and identification of novel targets for anti-tumor drug discovery. Moreover, LCOs provide supplementary decision-making factors to enhance the current precision medicine for lung cancer, thereby addressing the limitations associated with pathology-guided approaches in managing refractory lung cancer. This article presents a comprehensive review on the construction methods and potential applications of LCOs in both preclinical and clinical research. It highlights the significance of LCOs in biomarker exploration, drug resistance investigation, target identification, clinical precision drug screening, as well as microfluidic technology-based high-throughput drug screening strategies. Additionally, it discusses the current limitations and future prospects of this field.

Organoids in Lung Cancer Management

Non-small Cell Lung Cancer Organoids: Advances and Challenges in Current Applications.

Organoids in lung cancer: A teenager with infinite growth potential

Lung cancer organoids: models for preclinical research and precision medicine

Recent advances in lung cancer organoid (tumoroid) research (Review)

Applications of lung cancer organoids in precision medicine: from bench to bedside

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review

Lung Organoids: Systematic Review of Recent Advancements and its Future Perspectives

Application of organoids in precision immunotherapy of lung cancer (Review)

Lung Cancer Organoids: The Rough Path to Personalized Medicine

Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?

Lung cancer organoids, a promising model still with long way to go

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications

[Application and Research Progress of Lung Cancer Organoid in Precision Medicine for Lung Cancer]

Scientific Validation and Clinical Application of Lung Cancer Organoids

Lung organoids: current uses and future promise

Using Patient-Derived Organoids to Predict Locally Advanced or Metastatic Lung Cancer Tumor Response: A Real-World Study

Using 3-Dimensional Cultures to Propagate Genetically Modified Lung Organoids